Fulgent Genetic (FLGT) to Release Earnings on Monday
Fulgent Genetic (NASDAQ:FLGT) is scheduled to be posting its quarterly earnings results after the market closes on Monday, November 6th.
Fulgent Genetic (NASDAQ:FLGT) last announced its earnings results on Monday, August 7th. The company reported $0.02 EPS for the quarter, meeting the consensus estimate of $0.02. The business had revenue of $4.64 million for the quarter, compared to the consensus estimate of $5.03 million. Fulgent Genetic had a negative return on equity of 0.02% and a negative net margin of 0.42%. On average, analysts expect Fulgent Genetic to post $0.07 EPS for the current fiscal year and $0.2 EPS for the next fiscal year.
Shares of Fulgent Genetic (FLGT) traded up 0.79% during midday trading on Monday, hitting $3.85. The company had a trading volume of 77,650 shares. The company’s 50 day moving average is $4.54 and its 200 day moving average is $4.54. The firm’s market cap is $68.30 million. Fulgent Genetic has a one year low of $3.60 and a one year high of $13.90.
COPYRIGHT VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/10/30/fulgent-genetic-flgt-to-release-earnings-on-monday.html.
Several analysts have recently issued reports on the company. Piper Jaffray Companies reiterated an “overweight” rating and set a $7.00 price target (down previously from $10.00) on shares of Fulgent Genetic in a research note on Wednesday, August 9th. Zacks Investment Research downgraded Fulgent Genetic from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. ValuEngine upgraded Fulgent Genetic from a “sell” rating to a “hold” rating in a research note on Monday, October 2nd. Finally, Credit Suisse Group decreased their price target on Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday, August 8th.
In other news, CFO Paul Kim sold 6,134 shares of the company’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $5.71, for a total transaction of $35,025.14. Following the completion of the sale, the chief financial officer now owns 388,602 shares in the company, valued at approximately $2,218,917.42. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 58.80% of the company’s stock.
Fulgent Genetic Company Profile
Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.
Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with MarketBeat.com's FREE daily email newsletter.